BIOTRONIK Wins Supplier of the Year Award Third Consecutive Year Germany’s Top Hospital Network Prospitalia Honors the Company’s Sustained Excellence
For the third year in a row, BIOTRONIK has been named “Supplier of the Year” in the category Medical by Prospitalia. This hattrick sets a new benchmark and distinction that no other company has ever achieved in the Medtech field. As a company, we are honored by the trust and recognition from our clinical partners.
The Prospitalia Supplier Award emphasizes BIOTRONIK’s unwavering commitment to quality, reliability, and customer-centric service in a highly competitive market. The award, presented during the Prospitalia Congress 2025 in Frankfurt, recognizes outstanding performance across key criteria including economic efficiency, supply security, product quality, and customer service. Receiving high rankings in all the above categories affirms BIOTRONIK’s consistent excellence in the healthcare sector.
“This award is a powerful testimony of the quality and reliability that define our work,” said Ralf Hoffmeister, Director Sales Germany at BIOTRONIK. “At BIOTRONIK, we believe that long-term partnerships are the foundation for better patient care. This recognition drives us to stay ahead of the curve and continue setting new standards in the industry.”
BIOTRONIK’s continued leadership reflects not only the exceptional quality of its products but also its outstanding service culture. The award also underlines the company’s role as a trusted and strategic partner in the healthcare system towards active implantable and connected healthcare technologies.
The Prospitalia supplier evaluation is one of the most comprehensive in the German healthcare market, representing over 85% of the purchasing volume of its member hospitals. In 2024, 57 medical suppliers were assessed by acute care hospitals based on defined performance metrics. The award ceremony, with over 700 participants, highlighted the importance of supplier performance in clinical decision-making and internal quality assessments.
-END-
About BIOTRONIK
For over 60 years, BIOTRONIK has stood at the forefront of medical technology, pioneering breakthrough innovations that are transforming the lives of millions affected by heart disease and chronic pain. Rooted in a deep purpose to seamlessly harmonize technology with the human body, we engineer trusted, life-changing therapies through our advanced active implants in Cardiac Rhythm Management, Monitoring, and Neuromodulation, while providing cutting-edge solutions in Electrophysiology. From creating Germany’s first pacemaker in 1963 to breaking new ground in digital technologies and Conduction System Pacing today, BIOTRONIK is continuously raising the bar for quality, performance, and innovation. Headquartered in Berlin, our global reach spans over 100 countries across the Americas, EMEA, and Asia—bringing bold, future-ready solutions that are shaping the next generation of medical technology.
Media Contact
BIOTRONIK Press Office: press@biotronik.com
More Press Releases
-
Image
BERLIN, GermanyBIOTRONIK Driving the Future of Active Device BusinessBIOTRONIK Driving the Future of Active Device Business
BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next
-
Image
BERLIN, GermanyPress ReleaseDigital Heart Summit 2024: Pioneering the Future of Cardiology Through Digital Innovation
The Digital Heart Summit 2024, held in Berlin on October 25-26th, concluded with resounding success, bringing together leading minds in eHealth to explore the cutting-edge innovations in digital cardiology. The summit attracted over 100 cardiologists, researchers, and tech innovators from across Europe, making it an excellent platform for interactive exchange and diverse insights in this fast-evolving field. Throughout the two-day event, attendees engaged in discussions on the latest advancements in artificial intelligence, telemedicine, and wearable health devices. These technologies are
-
Image
SINGAPOREPress ReleaseBIOTRONIK Opens New Asia-Pacific Hub in Singapore
BIOTRONIK announced today the opening of its new Asia Pacific Manufacturing and Research Hub. The 20,000 m² site will serve as the company’s central hub in Asia-Pacific, with hundreds of employees working in manufacturing, quality, research & development (R&D), and sales and marketing. BIOTRONIK, founded in Berlin, Germany, in 1963 is a pioneer in implantable pacemakers, defibrillators, and vascular intervention for 60 years. BIOTRONIK’s presence in Singapore began in 2012, and in 2016, the company inaugurated its first manufacturing site, complementing its high-quality manufacturing sites in
-
Image
BERLIN, GermanyPress ReleaseAI-Supported Telemedicine Platform Aims to Improve the Health of Patients After Myocardial Infarction and Prevent Reinfarctions
The TIMELY consortium announced today the enrollment of the first patient in the randomized controlled clinical TIMELY trial. The TIMELY study investigates to what extent the AI-supported TIMELY platform improves the health of myocardial infarction (MI) patients and other patients with coronary heart disease after cardiac rehabilitation. Around 1.8 million people in the European Union die each year from coronary heart disease. 1 To prevent reinfarctions, patients receive cardiac rehabilitation to support necessary changes in lifestyle habits, such as diet and increased physical activity
-
Image
StatementA Message to Our Valued Customers and Their Patients
As the COVID-19 pandemic continues, we are conscious of the enormous strain that you are all under. We share your concerns about the spread of the virus and the disruption it is causing globally. We are doing what we can to help minimize this disruption and to provide support so that you can focus on the critical task of saving lives. To this end, we would like to inform you of the following: